From: EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies
Conditions | EZH2 inhibitor | Other drugs | Phase | Trial information |
---|---|---|---|---|
B-NHL, solid advanced tumors | Tazemetostat (oral versus IV) | N/A | 1 | Recruiting (NCT03010982) |
B-NHL and advanced solid tumors | Tazemetostat | Fluconazole, Omeprazole, Repaglinide | 1 | Active, not recruiting (NCT03028103) |
Advanced B-NHL or solid tumors with liver dysfunction | Tazemetostat | N/A | 1 | Suspended (External information) (NCT03217253) |
Relapsed/refractory DLBCL | Tazemetostat | Atezolizumab | 1 | Active, not recruiting (NCT02220842) |
B-NHL, advanced solid tumors | Tazemetostat | Alone or combined with prednisolone | 1/2 | Recruiting; preliminary results for phase 1 [39] (NCT01897571) |
RR FL and DLBCL with or without EZH2 mutation | Tazemetostat | N/A | 2 | |
RR B-NHL with confirmed EZH2 mutation | Tazemetostat | N/A | 2 | Not yet recruiting (NCT03456726) |
Paediatric patients with NHL, histiocytic disorder or solid tumor with EZH2, SMARCB1 or SMARCA4 mutation | Tazemetostat | N/A | 2 | Suspended (External information) (NCT03213665) |
Patients previously enrolled in Tazemetostat trials | Tazemetostat | Depends on previous trial regimen | 2 | Recruiting (NCT02875548) |
FL, DLBCL, resistant prostate cancer, RR small cell lung carcinoma | PF-06821497 | N/A | 1 | Recruiting (NCT03460977) |
B-cell lymphomas | CPI-1205 | N/A | 1 | Active, not recruiting (NCT02395601) |
Advanced DLBCL and other malignancies | MAK683 | N/A | 1/2 | Recruiting (NCT02900651) |